TANDEM DIABETES CARE, INC. Financials Tandem Diabetes Care, Inc.
Equities
TNDM
US8753722037
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.07 USD | -1.75% |
|
-3.59% | +72.41% |
| Jun. 03 | Tandem Diabetes Care Insider Sold Shares Worth $258,400, According to a Recent SEC Filing | MT |
| May. 30 | Redburn Atlantic Starts Tandem Diabetes Care With Buy Rating, $60 Price Target | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,523 | 5,951 | 9,563 | 2,890 | 1,929 | 3,357 | - | - |
| Enterprise Value (EV) 1 | 3,346 | 6,059 | 9,221 | 2,890 | 1,746 | 3,213 | 3,246 | 3,261 |
| P/E ratio | -142 x | -171 x | 627 x | -30.6 x | -8.62 x | -31.4 x | -46.7 x | -83.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.72 x | 11.9 x | 13.6 x | 3.61 x | 2.58 x | 3.87 x | 3.5 x | 3.18 x |
| EV / Revenue | 9.24 x | 12.1 x | 13.1 x | 3.61 x | 2.34 x | 3.7 x | 3.38 x | 3.09 x |
| EV / EBITDA | -314 x | 2,429 x | 253 x | 54.1 x | -190 x | 1,668 x | 86.3 x | 52.8 x |
| EV / FCF | 150 x | -2,212 x | 94.9 x | - | -29.8 x | -189 x | 255 x | 52.1 x |
| FCF Yield | 0.67% | -0.05% | 1.05% | - | -3.36% | -0.53% | 0.39% | 1.92% |
| Price to Book | 17.9 x | 15.9 x | 22.4 x | - | 6.13 x | 11.2 x | 10.7 x | 9.75 x |
| Nbr of stocks (in thousands) | 59,093 | 62,195 | 63,533 | 64,299 | 65,210 | 64,590 | - | - |
| Reference price 2 | 59.61 | 95.68 | 150.5 | 44.95 | 29.58 | 51.98 | 51.98 | 51.98 |
| Announcement Date | 2/24/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 362.3 | 498.8 | 702.8 | 801.2 | 747.7 | 868.6 | 960.4 | 1,055 |
| EBITDA 1 | -10.65 | 2.494 | 36.5 | 53.41 | -9.191 | 1.926 | 37.6 | 61.82 |
| EBIT 1 | -16.72 | -7.957 | 22.65 | -45.84 | -112.6 | -118.2 | -85.8 | -63.35 |
| Operating Margin | -4.62% | -1.6% | 3.22% | -5.72% | -15.06% | -13.6% | -8.93% | -6% |
| Earnings before Tax (EBT) 1 | -24.6 | -36.28 | 15.9 | -92.85 | -220.3 | -108.4 | -78.9 | -48.3 |
| Net income 1 | -24.75 | -34.38 | 15.57 | -94.59 | -222.6 | -109.4 | -72.3 | -41.3 |
| Net margin | -6.83% | -6.89% | 2.21% | -11.81% | -29.77% | -12.59% | -7.53% | -3.91% |
| EPS 2 | -0.4200 | -0.5600 | 0.2400 | -1.470 | -3.430 | -1.656 | -1.113 | -0.6204 |
| Free Cash Flow 1 | 22.36 | -2.739 | 97.18 | - | -58.61 | -17 | 12.73 | 62.54 |
| FCF margin | 6.17% | -0.55% | 13.83% | - | -7.84% | -1.96% | 1.33% | 5.93% |
| FCF Conversion (EBITDA) | - | - | 266.26% | - | - | - | 33.86% | 101.16% |
| FCF Conversion (Net income) | - | - | 624.3% | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 210 | 175.9 | 200.3 | 205.1 | 220.5 | 169.4 | 195.9 | 185.6 | 196.8 | 191.7 | 205.9 | 220.4 | 249.7 | 214.2 | 228.6 |
| EBITDA 1 | 16.26 | 6.4 | 11.44 | 9.866 | 25.7 | -20.16 | 5.265 | 1.455 | 4.252 | -14.45 | -7.147 | 7.388 | 17.19 | -4.321 | 0.5033 |
| EBIT 1 | 12.74 | -15.34 | -12.24 | -15.88 | -2.385 | -127.8 | -38.81 | -23.31 | -22.52 | -40.53 | -37.22 | -24.19 | -13.77 | -29.45 | -26.6 |
| Operating Margin | 6.07% | -8.72% | -6.11% | -7.74% | -1.08% | -75.46% | -19.81% | -12.56% | -11.44% | -21.15% | -18.08% | -10.98% | -5.51% | -13.75% | -11.64% |
| Earnings before Tax (EBT) 1 | 11.14 | -16.44 | -12.95 | -47.35 | -16.11 | -123.6 | -34.63 | -30.73 | -31.31 | -39.53 | -35.21 | -22.4 | -10.9 | -34.67 | -26.81 |
| Net income 1 | 10.81 | -14.72 | -15.06 | -48.97 | -15.85 | -123.9 | -35.78 | -32.96 | -30 | -42.72 | -34.42 | -21.76 | -11.3 | -27.22 | -21.77 |
| Net margin | 5.15% | -8.37% | -7.52% | -23.87% | -7.19% | -73.13% | -18.26% | -17.76% | -15.25% | -22.29% | -16.72% | -9.87% | -4.53% | -12.7% | -9.52% |
| EPS 2 | 0.1600 | -0.2300 | -0.2300 | -0.7600 | -0.2500 | -1.920 | -0.5500 | -0.5100 | -0.4600 | -0.6500 | -0.5312 | -0.3207 | -0.1511 | -0.4128 | -0.3321 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/22/22 | 5/4/22 | 8/3/22 | 11/2/22 | 2/22/23 | 5/3/23 | 8/3/23 | 11/1/23 | 2/21/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 108 | - | - | - | - | - | - |
| Net Cash position 1 | 176 | - | 342 | - | 183 | 145 | 111 | 96.1 |
| Leverage (Debt/EBITDA) | - | 43.45 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 22.4 | -2.74 | 97.2 | - | -58.6 | -17 | 12.7 | 62.5 |
| ROE (net income / shareholders' equity) | -15.2% | -12.3% | 3.89% | -21.7% | -27.1% | -36.8% | -21.8% | -9.04% |
| ROA (Net income/ Total Assets) | -9.3% | -6.6% | 1.92% | -9.66% | -10.2% | -8.4% | -5% | -1.2% |
| Assets 1 | 266.2 | 521.3 | 810.8 | 979 | 2,189 | 1,302 | 1,446 | 3,442 |
| Book Value Per Share 2 | 3.330 | 6.010 | 6.730 | - | 4.830 | 4.640 | 4.850 | 5.330 |
| Cash Flow per Share 2 | 0.7200 | 0.4000 | 1.730 | - | -0.4900 | -0.6200 | 1.050 | 1.600 |
| Capex 1 | 19.5 | 27.4 | 14.2 | - | 26.8 | 29.3 | 30.9 | 36.4 |
| Capex / Sales | 5.39% | 5.49% | 2.02% | - | 3.58% | 3.37% | 3.22% | 3.45% |
| Announcement Date | 2/24/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
51.98
USD
Average target price
49.2
USD
Spread / Average Target
-5.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +75.73% | 3.36B | |
| -6.54% | 179B | |
| -0.32% | 108B | |
| -2.05% | 69.03B | |
| -7.14% | 45.83B | |
| +12.24% | 45.39B | |
| +8.60% | 43.17B | |
| +15.37% | 29.89B | |
| +13.65% | 25.49B | |
| -6.64% | 23.95B |
- Stock Market
- Equities
- TNDM Stock
- Financials Tandem Diabetes Care, Inc.
